DelveInsight has launched a new report on Advanced liver cancer Pipeline Insight, 2020
Advanced liver cancer Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Advanced liver cancer market. A detailed picture of the Advanced liver cancer pipeline landscape is provided, which includes the disease overview and Advanced liver cancer treatment guidelines. The assessment part of the report embraces in-depth Advanced liver cancer commercial assessment and clinical assessment of the Advanced liver cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced liver cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Advanced Liver Cancer is a stage IV Liver Cancer in which the cancer has spread to nearby lymph nodes and may have grown into nearby blood vessels or organs. It does not often metastasize but when it does, it is most likely to spread to the lungs and bones. It is further categorized into IVA and IVB stages. In stage IVA the cancer have grown into blood vessels or the organs around the liver and has spread to lymph nodes but not to other parts of the body. While in stage IVB the cancer spread to another part of the body such as the lungs or bones.
Request for free sample page
Pipeline Development Activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Advanced liver cancer with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Advanced liver cancer treatment.
- Advanced liver cancer key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Advanced liver cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Report key facts:-
1. According to Japanese Journal of Clinical Oncology, the proportion of early-stage Hepatocellular Carcinoma (HCC) is about 65%, whereas only 5% patients are present with advanced-stage in Japan.
2. According to Cancer Research UK, Incidence rates are significantly higher in males than females in a number of (mainly older) age groups .
3. According to Centers for Disease Control and Prevention, estimates that, about 33,000 people get liver cancer, and about 26,000 people die from the disease each year in the United States
Some of key major companies are working on this disease which are given below:-
1. Ono Pharmaceutical Co. Ltd
2. Benhealth Biopharmaceutical Co., Ltd
3. Millennium Pharmaceutical Co. Ltd
Name of drugs covered which are given below:-
2. CIK and CD3-MUC1
1. Report Introduction
2. Advanced liver cancer
3. Advanced liver cancer Current Treatment Patterns
4. Advanced liver cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Advanced liver cancer Late Stage Products (Phase-III)
7. Advanced liver cancer Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Advanced liver cancer Discontinued Products
13. Advanced liver cancer Product Profiles
14. Advanced liver cancer Key Companies
15. Advanced liver cancer Key Products
16. Dormant and Discontinued Products
17. Advanced liver cancer Unmet Needs
18. Advanced liver cancer Future Perspectives
19. Advanced liver cancer Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
22. About Delveinsight
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States